• IMCIVREE now commercially available in Canada, GCC states; German BBS launch underway • 12-month data planned for fall conference • Additional detail on development programs at 4Q R&D event 6 Investigational New Drug (IND) application on track to be filed by end of 2023 *Includes patent term adjustment and patent term extension. Heterozygous POMC/PCSK1 insufficiency *Estimated prevalence of U.S. patients based on company estimates; does not include ex-U.S. prevalence estimates. 53,000 patients in the U.S. ...